Etelcalcetide

Calcium-sensing Receptor Agonist — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Etelcalcetide is an onp drug in the Calcium-sensing Receptor Agonist class catalogued in DrugCentral. It was first approved by the EMA in 2016. Its mechanism of action is classified as Increased Calcium-sensing Receptor Sensitivity. DrugCentral lists 1 molecular target, including CASR. Recorded indications include Secondary hyperparathyroidism.

• Approval status: onp (first approved 2016 by the EMA).
• Drug class: Calcium-sensing Receptor Agonist.
• Mechanism of action: Increased Calcium-sensing Receptor Sensitivity.
• Molecular targets: CASR (1 listed in DrugCentral).
• Indications: Secondary hyperparathyroidism.
• ATC code: H05BX04 (Other anti-parathyroid agents).
• Molecular formula: C38H73N21O10S2; molecular weight 1048.26 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Secondary hyperparathyroidism

Mechanism & targets

• Mechanism of action (MoA): Increased Calcium-sensing Receptor Sensitivity
• Established pharmacologic class: Calcium-sensing Receptor Agonist

Molecular targets (1)

Target	Gene	Action	Activity
Extracellular calcium-sensing receptor	CASR	agonist	EC50 4.60

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2017-02-07	FDA	—	KAI PHARMS INC
2016-11-11	EMA	—	Amgen Europe B.V.

ATC classification

ATC code	Therapeutic hierarchy
H05BX04	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CALCIUM HOMEOSTASIS › ANTI-PARATHYROID AGENTS › Other anti-parathyroid agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Shunt stenosis	1490.2
Shunt occlusion	824.3
Underdose	798.7
Blood parathyroid hormone increased	726.0
Hypocalcaemia	442.0
Blood calcium decreased	401.8
Peripheral arterial occlusive disease	249.0
Product storage error	225.9
Blood parathyroid hormone abnormal	202.4
Angina unstable	105.9
Shunt infection	104.6
Blood calcium increased	102.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Etelcalcetide is on its molecule page.

• Molecular formula: C₃₈H₇₃N₂₁O₁₀S₂
• Molecular weight: 1048.26 g/mol
• CAS number: 1262780-97-1
• InChIKey: ANIAZGVDEUQPRI-ZJQCGQFWSA-N
• PubChem CID: 71511839

C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Etelcalcetide used for?

DrugCentral lists the following indications for Etelcalcetide: Secondary hyperparathyroidism.

How does Etelcalcetide work?

Etelcalcetide is classified as Increased Calcium-sensing Receptor Sensitivity; its molecular targets in DrugCentral include CASR (agonist).

When was Etelcalcetide first approved?

Etelcalcetide was first approved by the EMA in 2016.

What drug class does Etelcalcetide belong to?

Etelcalcetide is in the Calcium-sensing Receptor Agonist class.

What is the chemical formula of Etelcalcetide?

Etelcalcetide has the molecular formula C38H73N21O10S2 and a molecular weight of 1048.26 g/mol.

Sources

• DrugCentral drug card 5181 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3545183 — compound record and bioactivity
• PubChem CID 71511839 — chemical identifiers
• DrugBank DB12865 — drug record
• FDA UNII 60ME133FJB — substance identity
• DailyMed: FDA labels for Etelcalcetide — current prescribing information (label search)
• UniProt P41180 (CASR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.